about
Risk stratification in patients with pulmonary hypertension undergoing transcatheter aortic valve replacement.Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER trial cohort--a analysis.Current management of calcific aortic stenosis.Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.The adverse impact of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosisChallenges facing early career academic cardiologists.Futility, benefit, and transcatheter aortic valve replacementSystemic inflammatory response syndrome after transcatheter or surgical aortic valve replacementPrognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement.National Institutes of Health Career Development Awards for Cardiovascular Physician-Scientists: Recent Trends and Strategies for SuccessClinical and Functional Outcomes Associated With Myocardial Injury After Transfemoral and Transapical Transcatheter Aortic Valve Replacement: A Subanalysis From the PARTNER Trial (Placement of Aortic Transcatheter Valves).Intra-Aortic Balloon Counterpulsation in Patients With Chronic Heart Failure and Cardiogenic Shock: Clinical Response and Predictors of StabilizationEffects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosisMultimorbidity in Older Adults with Aortic Stenosis.Delirium after surgical and transcatheter aortic valve replacement is associated with increased mortalityPreoperative pulmonary function tests predict mortality after surgical or transcatheter aortic valve replacement.Outcomes in Patients With Transcatheter Aortic Valve Replacement and Left Main Stenting: The TAVR-LM RegistryModulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension.Learning Alternative Access Approaches for Transcatheter Aortic Valve Replacement: Implications for New Transcatheter Aortic Valve Replacement Centers.Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes.BNP during exercise: a novel use for a familiar biomarker in aortic stenosis.Fixing the Valve, But Injuring the Kidneys, With Transcatheter Aortic Valve Replacement: Collateral Damage With Serious Consequences.Left ventricular mechanics in aortic stenosis: fancy tool or clinically useful?Multimarker Approach to Identify Patients With Higher Mortality and Rehospitalization Rate After Surgical Aortic Valve Replacement for Aortic StenosisTime to Treat Hypertension in Patients With Aortic StenosisACC/AATS/AHA/ASE/EACTS/HVS/SCA/SCAI/SCCT/SCMR/STS 2017 Appropriate use criteria for the treatment of patients with severe aortic stenosisActivin type II receptor signaling in cardiac aging and heart failureLow and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registryTranscatheter Aortic Valve Replacement in Patients With End-Stage Renal DiseaseManagement of Asymptomatic Severe Aortic Stenosis: Evolving Concepts in Timing of Valve ReplacementIncorporating the Patient Voice Into Shared Decision-Making for the Treatment of Aortic StenosisThe Authors' ReplyPriorities for Patient-Centered Research in Valvular Heart Disease: A Report From the National Heart, Lung, and Blood Institute Working Group2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: A Proposal to Optimize Care for Patients With Valvular Heart Disease: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, American Soc
P50
Q30355931-739A3DBE-BAF2-4D67-8DB8-97FC88012F4BQ30370788-67089DEF-FD95-4F27-89B6-E052114B66EAQ30435363-1A4B95AD-775E-402B-976D-7687948E13FFQ34046332-8E56C189-643D-489E-85D8-A260633C4BF0Q35002049-7EBD3CE5-7226-4968-9C2E-75F42DE61412Q35013233-B07AEE11-1F85-4AE1-BBCF-84F15E173D53Q35064751-A9369C06-36CA-4443-ACF2-F29D784940A0Q35154936-E609E7D1-00F8-4687-8DC2-FFF5505D6081Q36136687-D186C569-46EE-484A-947B-F0A15C6EA1DDQ36191063-EC1A0E22-C459-4029-BB11-7FDC4A87C81EQ36219512-EFD56FD8-D839-418E-B44C-312F6E2960D0Q36240491-2A18D61F-3411-4311-86AE-C19787C9B565Q36360615-3494D680-96C1-45E9-8443-6C2ADA7E5673Q36845578-66560C8F-3CD1-4527-9239-B6077B059B6EQ37382071-0E10A100-17C8-42DD-9874-27C8CFA8C97CQ37387645-10E48D01-1340-448E-B02B-82F8E81BC81BQ37387656-2A8AD8E1-82BC-4524-A114-C0D261FCF70AQ37799652-7D0A475F-C155-4A8B-A30A-3FE21C544687Q38409609-1682E44E-C54B-42E6-A865-1F5900B67F27Q46412153-7678A11B-EEA5-4148-A954-CE097810B245Q48657774-C6067278-C793-46B8-9646-5C13D0E73308Q50098466-053E5374-BFCB-4499-9CF0-8B389D6248A2Q53483569-1EA50676-583D-4C11-B3E3-C5A302B52E7DQ58554409-101B0812-C4E4-48B7-82A9-55310AD1660AQ59076452-A1445EAB-D2AC-4BB4-9597-9621691E5646Q92026374-31BFAC36-B1D3-4354-A8A8-7BC8277B14F6Q92177821-878AEF62-0170-47DD-B94A-C99A64D8087CQ92292916-4B0395C4-0661-481F-A607-0D9CE3549BD6Q92568215-C95A9DDB-80BF-4345-B39A-FF51FE622E23Q92770971-8CA5939C-22E7-41DD-8F11-9AD20E438EFEQ93029206-884C5975-2AFF-4213-B586-A064933DCB47Q93129795-5B97A98B-F4DA-415B-9590-41BD5287EFCCQ93191461-E2156870-5F17-40EE-A898-B17EF31D6DE1Q95464307-9D2F7286-83C7-4740-84E8-B8C239EE92E8
P50
description
physician
@en
wetenschapper
@nl
հետազոտող
@hy
name
Brian R. Lindman
@ast
Brian R. Lindman
@es
Brian R. Lindman
@nl
Brian R. Lindman
@sl
Brian Richard Lindman
@en
type
label
Brian R. Lindman
@ast
Brian R. Lindman
@es
Brian R. Lindman
@nl
Brian R. Lindman
@sl
Brian Richard Lindman
@en
prefLabel
Brian R. Lindman
@ast
Brian R. Lindman
@es
Brian R. Lindman
@nl
Brian R. Lindman
@sl
Brian Richard Lindman
@en
P106
P1153
36677607300
P21
P31
P496
0000-0002-6879-5343